Novo Nordisk A/S
CorpDigest
Novo Nordisk A/S
Company History
Founded 1989 in Bagsværd, Denmark
Last reviewed: 2026-06-08 · By Swet Parvadiya
Novo Nordisk A/S generated 290.42 billion DKK ($42.7 billion) in FY2024 net sales, operating as the undisputed global hegemon in incretin-based therapies that commands a 43.1% operating profit margin by focusing exclusively on high-margin patented biologics and peptide chemistry. The company's strategic identity was defined in 2017 when it launched Ozempic, followed by Wegovy in 2021, deliberately shifting its capital allocation toward chronic weight management and cardiovascular risk reduction. This pivot has resulted in a highly concentrated portfolio where growth is driven by the semaglutide franchise, which generated 215.2 billion DKK ($31.6 billion) in FY2024 sales, representing 74% of total company revenue. With 77,900 employees and a market capitalization of $550 billion, Novo Nordisk allocates 34.6 billion DKK annually to R&D, funding a pipeline of over 100 clinical projects and enabling aggressive manufacturing investments like the $16.5 billion Catalent acquisition. The company's future depends on its ability to execute a 15-20% constant currency sales CAGR through 2030, a target that requires the successful launch of next-generation assets like CagriSema and oral amycretin, and the continuous expansion of its dominant position in GLP-1 therapeutics to defend against Eli Lilly's tirzepatide.
Hans Christian Hagedorn was a Danish physician and researcher who played a pivotal role in the introduction of insulin to Scandinavia. After meeting Frederick Banting in Canada in 1923, Hagedorn worked with August Krogh to establish the Nordisk Insulinlaboratorium in Copenhagen. His background in clinical medicine gave him a unique perspective on the practical challenges of diabetes management, driving his focus on developing insulin formulations that required less frequent injections. During his tenure, he oversaw the development of protamine insulin and NPH insulin, which became the standard of care for diabetes treatment for decades. Hagedorn was also known for his commitment to making insulin affordable and accessible to all patients, a philosophy that remains core to Novo Nordisk's corporate culture. Despite the commercial success of the company, Hagedorn maintained a modest lifestyle and donated a significant portion of his wealth to medical research. He is widely respected in Denmark for his role in transforming diabetes from a fatal diagnosis into a manageable chronic condition.
Harald Pedersen was a Danish chemist and business executive who served as the CEO of Novo Terapeutisk Laboratorium from its founding in 1925 until the 1950s. He was the primary architect of Novo's early manufacturing strategy, focusing on industrial-scale production of insulin and other biological products. Pedersen's career in chemistry spanned over four decades, during which he held various leadership positions in research and operations. His leadership style was characterized by a focus on scientific rigor and process efficiency, qualities that were essential in navigating the complex challenges of large-scale biologics manufacturing. After stepping down as CEO, Pedersen remained active in the company as a board member and advisor, serving on the boards of several major Danish corporations. He is widely respected in Denmark for his role in creating a global biological manufacturing leader and for his commitment to maintaining the company's headquarters in Denmark.
August Krogh and Hans Christian Hagedorn founded the Nordisk Insulinlaboratorium in Copenhagen, securing the licensing rights to produce insulin for the Scandinavian countries.
Harald Pedersen and a group of Danish physicians founded Novo Terapeutisk Laboratorium to produce insulin and other biological products using industrial-scale fermentation processes.
The $1.5 billion merger of Novo Industri and Nordisk Insulinlaboratorium was completed, creating Novo Nordisk A/S as one of the world's largest insulin manufacturers.
Novo Nordisk launched Insulin aspart, the first rapid-acting insulin analog, which significantly improved postprandial glycemic control and established the company as a leader in diabetes care.
Novo Nordisk launched Insulin detemir, a long-acting basal insulin analog with a flat action profile and reduced risk of hypoglycemia compared to NPH insulin.
Novo Nordisk launched Victoza, the first once-daily GLP-1 receptor agonist, marking the company's strategic pivot from insulin to incretin-based therapies.
Novo Nordisk launched Ozempic, a once-weekly GLP-1 receptor agonist for type 2 diabetes, which became the fastest-growing diabetes drug in history.
Novo Nordisk launched Wegovy, a high-dose formulation of semaglutide for chronic weight management, demonstrating an average weight loss of 14.9% in the STEP-1 trial.
Novo Nordisk announced the results of the SELECT trial, demonstrating a 20% reduction in major adverse cardiovascular events for semaglutide 2.4mg in non-diabetic obese patients.
Novo Holdings acquired Catalent for $16.5 billion, securing three critical fill-finish facilities to eliminate the physical supply constraints that limited Wegovy sales.
Novo Nordisk reported 290.42 billion DKK ($42.7 billion) in net sales for FY2024, with operating profit reaching 125.3 billion DKK and free cash flow at 91.2 billion DKK.
Novo Holdings acquired Catalent for $16.5 billion to secure three critical fill-finish facilities in Indiana, Belgium, and Italy, eliminating the physical supply constraints that limited Wegovy sales.
Novo Nordisk acquired Dicerna for $3.3 billion to gain control of its proprietary RNA interference (RNAi) technology platform, specifically the GalNAc conjugate technology for targeted liver delivery.
Novo Nordisk acquired Actual Analytics, a healthcare data analytics company, for $150 million to enhance its commercial intelligence and real-world evidence capabilities.